Martin J Donovan

This inventor holds 27 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Respira Therapeutics, Inc., Xeris Pharmaceuticals, Inc., The University of New Mexico. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin J Donovan. Retrieved from https://idiyas.com/inventor/martin-j-donovan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 13)

% Patents Active = 96.3

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 125(Granted Patents)

Location History:

Albuquerque, NM (US) (2012 - 2014)
Santa Fe, NM (US) (2019)
El Paso, TX (US) (2013 - 2022)
Austin, TX (US) (2015 - 2024)
Chicago, IL (US) (2019 - 2024)

Company Filing History:

14 out of 14

Respira Therapeutics, Inc.

patents

9 out of 29

Xeris Pharmaceuticals, Inc.

patents

4 out of 943

The University of New Mexico

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Levothyroxine Compositions

PDE5 Inhibitors

Pulmonary Hypertension

Therapeutic Formulations

Dry Powder Inhaler

Drug Delivery Systems

Aprotic Polar Solvents

Powder Dispersion Methods

Microparticle Coating

Syringes and Kits

Inhalation Powders

Swellable Particles

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12751937 - Stable levothyroxine compositions in aprotic polar solvents (2026-10-06),

2. 12691089 - Stable levothyroxine compositions in aprotic polar solvents (2026-07-28),

3. 12514837 - Stable levothyroxine compositions in aprotic polar solvents (2026-01-06),

4. 12364701 - PDE5 inhibitor powder formulations and methods relating thereto (2025-07-22),

5. 12263174 - Methods and compositions for treatment of pulmonary hypertension and other lung disorders (2025-04-01),

6. 11957736 - Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same (2024-04-16),

7. 11911390 - PDE5 inhibitor powder formulations and methods relating thereto (2024-02-27),

8. 11806314 - PDE5 inhibitor powder formulations and methods relating thereto (2023-11-07),

9. 11590205 - Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents (2023-02-28),

10. 11576951 - Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same (2023-02-14),

11. 11491161 - Methods and compositions for treatment of pulmonary hypertension and other lung disorders (2022-11-08),

12. 11491160 - Methods and compositions for treatment of pulmonary hypertension and other lung disorders (2022-11-08),

13. 11471623 - Powder dispersion methods and devices (2022-10-18),

14. 11129940 - Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes (2021-09-28),

15. 10912778 - Methods for treatment of pulmonary hypertension (2021-02-09),

Sure, here's the article on inventor Martin J Donovan based on the data provided:

Title: The Innovative Mind of Martin J Donovan: Transforming Healthcare Through Inventive Powder Formulations

Introduction: Martin J Donovan, a prolific inventor hailing from El Paso, TX, has made significant contributions to the field of healthcare through his groundbreaking inventions. With an impressive portfolio of 21 patents to his name, Donovan continues to push the boundaries of innovation in pharmaceuticals.

Latest Patents: Among his latest patents is the development of PDE5 inhibitor powder formulations and related methods. These novel dry powder compositions, including PDE5 inhibitors like vardenafil, offer advanced treatment options for various diseases. With a concentration of active agents exceeding 2% by weight, these formulations demonstrate Donovan's commitment to efficacy and patient care.

Career Highlights: Donovan has made a mark in renowned companies such as Respira Therapeutics, Inc. and Xeris Pharmaceuticals, Inc., where he has played a pivotal role in research and development. His expertise and dedication have led to the successful commercialization of several innovative products, establishing him as a key figure in the pharmaceutical industry.

Collaborations: Throughout his career, Donovan has collaborated with industry experts such as Hugh Smyth and Robert Curtis. Together, they have brought forth cutting-edge solutions and paved the way for novel drug delivery systems. Donovan's collaborative spirit and passion for innovation have fostered a culture of excellence in the workplace.

Conclusion: In conclusion, Martin J Donovan stands out as a visionary inventor who continues to drive advancements in healthcare through his pioneering work in powder formulations. His relentless pursuit of excellence and commitment to improving patient outcomes exemplify the essence of innovation in the pharmaceutical sector. Donovan's legacy serves as an inspiration for future inventors and underscores the transformative power of inventions in shaping the future of medicine.

I hope this article provides a comprehensive overview of Martin J Donovan's remarkable contributions to the field of pharmaceutical innovation. If you require any further information or details, feel free to reach out.

Profile summary based on public USPTO records.